Streetbeat News

SAVA

Cassava Sciences, Inc.

https://www.cassavasciences.com

Industry

Biotechnology

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Open

26.40

Mkt cap

1.2B

Volume

1.6M

High

27.16

P/E Ratio

-8.95

52-wk high

42.20

Low

24.65

Div yield

N/A

52-wk low

8.79

Cassava Sciences shares are under scrutiny as Adam Feuerstein tweets about Matt Nachtrab, a retail investor who previously bought $70M of SAVA, starting to sell his stake.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 5:41 pm

Cassava Sciences has appointed Rick Barry as its new CEO. This leadership change could influence the company's strategic direction and investor sentiment.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 12:43 pm

Cassava Sciences has been granted a U.S. patent for 'Solid Polymorphs of a FLNA-Binding Compound and Its Hydrochloride Salts'. This patent could enhance their intellectual property portfolio and potentially impact their market position.

Portfolio Pulse from Benzinga Newsdesk

August 20, 2024 | 7:09 pm

The article highlights unusual options activity for nine healthcare stocks: PFE, IBRX, VRNA, SAVA, NBIX, EW, MRK, BPMC, and EXAS. The sentiment for these options varies from neutral to bearish and bullish, indicating potential short-term price movements.

Portfolio Pulse from Benzinga Insights

August 13, 2024 | 5:35 pm

HC Wainwright & Co. analyst Vernon Bernardino has reiterated a Neutral rating on Cassava Sciences (NASDAQ:SAVA).

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:21 am

Rodman & Renshaw analyst Elemer Piros has reiterated a Buy rating on Cassava Sciences (NASDAQ:SAVA) and maintained a price target of $107.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 6:29 pm

Cassava Sciences (SAVA) shares see increased volume as traders circulate unconfirmed analyst comments suggesting confirmed guidance for the completion of its first pivotal Alzheimer's trial by the end of 2024 and a potential settlement of an SEC investigation. Analysts reiterate their buy rating and $107 price target.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 6:04 pm

Cassava Sciences expects net cash use in operations for the second half of 2024 to be $80M-$90M, including a $40M loss contingency related to SEC investigation discussions. The company estimates year-end 2024 cash at $117M-$127M.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:05 pm

Cassava Sciences reported a Q2 2024 GAAP EPS of $0.13, which may not be comparable to the estimated $(0.40).

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:03 pm

Cassava Sciences (NASDAQ:SAVA) has significantly outperformed the market over the past 5 years, with an annualized return of 77.29% and an average annual return of 89.51%. A $100 investment in SAVA 5 years ago would be worth $2,431.06 today. The company currently has a market capitalization of $1.44 billion.

Portfolio Pulse from Benzinga Insights

August 07, 2024 | 8:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.